Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PRTK
CUSIP89354M10
Phone617-807-6600
Debt
Debt-to-Equity Ratio0.47
Current Ratio8.06
Quick Ratio8.06
Price-To-Earnings
Trailing P/E Ratio-3.36
Forward P/E Ratio-2.98
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.62 million
Price / Sales27.42
Cash FlowN/A
Price / CashN/A
Book Value$2.65 per share
Price / Book4.13
Profitability
EPS (Most Recent Fiscal Year)($3.30)
Net Income$-89,060,000.00
Net Margins-707.08%
Return on Equity-87.29%
Return on Assets-50.20%
Miscellaneous
Employees83
Outstanding Shares31,600,000
Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) posted its quarterly earnings data on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.03. The specialty pharmaceutical company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.02 million. Paratek Pharmaceuticals had a negative net margin of 707.08% and a negative return on equity of 87.29%. View Paratek Pharmaceuticals' Earnings History.
What price target have analysts set for PRTK?
7 Wall Street analysts have issued 1 year target prices for Paratek Pharmaceuticals' stock. Their predictions range from $36.00 to $55.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $45.00 in the next twelve months. View Analyst Ratings for Paratek Pharmaceuticals.
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include Theravance Biopharma (TBPH), IMMURON Ltd/S (IMRN), Arrowhead Pharmaceuticals (ARWR), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Wave Life Sciences (WVE), Revance Therapeutics (RVNC), Zai Lab (ZLAB), Retrophin (RTRX), Eagle Pharmaceuticals (EGRX), Intra-Cellular Therapies (ITCI), Esperion Therapeutics (ESPR), TG Therapeutics Inc common stock (TGTX), Reata Pharmaceuticals (RETA) and Epizyme (EPZM).
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Bigham, Chairman & CEO (Age 60)
- Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 59)
- Mr. Douglas W. Pagán, Chief Financial Officer (Age 46)
- Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 51)
Has Paratek Pharmaceuticals been receiving favorable news coverage?
Media headlines about PRTK stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a news impact score of 0.10 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 47.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Paratek Pharmaceuticals' major shareholders?
Paratek Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Highland Capital Management LP (3.04%), C WorldWide Group Holding A S (1.58%), Northern Trust Corp (1.14%), Water Island Capital LLC (0.81%) and JPMorgan Chase & Co. (0.72%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Michael Bigham and Robert S Radie. View Institutional Ownership Trends for Paratek Pharmaceuticals.
Which major investors are selling Paratek Pharmaceuticals stock?
PRTK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, C WorldWide Group Holding A S, Prosight Management LP, JPMorgan Chase & Co. and Opus Point Partners Management LLC. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham and Robert S Radie. View Insider Buying and Selling for Paratek Pharmaceuticals.
Which major investors are buying Paratek Pharmaceuticals stock?
PRTK stock was purchased by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Omni Partners LLP, BlackRock Inc., California Public Employees Retirement System, Water Island Capital LLC, A.R.T. Advisors LLC, Trellus Management Company LLC and Northern Trust Corp. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.
How do I buy shares of Paratek Pharmaceuticals?
Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of PRTK stock can currently be purchased for approximately $10.95.
How big of a company is Paratek Pharmaceuticals?
Paratek Pharmaceuticals has a market capitalization of $336.50 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.
How can I contact Paratek Pharmaceuticals?
Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]
MarketBeat Community Rating for Paratek Pharmaceuticals (PRTK)
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
